Adeno-associated virus (AAV) is a promising gene vector based on a single-stranded (ss) DNA virus. Its transgene expression requires the conversion of ssDNA to doublestranded (ds) genome, a slow process responsible for the delayed transduction and occasional inefficiency. By mutating the inverted terminal repeat, we have made novel AAV vectors that predominantly package the self-complementary dsDNA genome. The dsAAV consistently demonstrated superior and accelerated transduction in vitro and in vivo. Dramatic increases in transgene expression were observed in most of the cell lines examined, including B16 melanoma and 3LL lung cancer that are difficult to be transduced by the conventional ssAAV vectors. Similar increases were also observed in vivo in a variety of tissues including muscle and liver. The dsAAV transduced a vast majority of the hepatocytes for more than 6 months, while the ssAAV transduced only a small fraction. In addition to circumventing the requirement for DNA synthesis, the dsAAV exhibited higher in vivo DNA stability and more effective circularization than the ssAAV, suggesting potential molecular mechanisms for the faster, stronger and prolonged transgene expression.
Introduction
Gene vectors derived from adeno-associated virus (AAV) can infect both dividing and nondividing cells in vitro and in vivo, establishing long-term and efficient transgene expression with minimal toxicity and cellular immune responses. 1 However, unlike other DNA-based viral and nonviral vectors such as adenovirus and plasmid, AAV packages and delivers a single-stranded (ss) DNA genome that is transcriptionally inactive until it is converted into a double-stranded (ds) template. The ssDNA to dsDNA conversion is a well-documented, rate-limiting step involving either the de novo synthesis of the second-strand DNA 2, 3 or the annealing of the plus and minus strands from two separate viral particles coinfected into the same cell. 4 This process contributes in part to the slow onset of transgene expression, especially in vivo, where a few weeks are often required to achieve significant transgene expression after vector delivery. The delayed transgene expression limits the usefulness of AAV vectors for applications that require immediate therapeutic intervention. [5] [6] [7] Another limitation of AAV vectors (eg, AAV2) is in the liver where only a few percent of the hepatocytes can be transduced despite the use of high vector doses. 8, 9 Although such efficiency is sufficient for many gene therapy purposes, [10] [11] [12] it is insufficient for others such as therapy for hepatitis (eg, ribozyme or siRNA strategies) and for certain metabolic diseases that require the majority of the liver cells to be transduced. In addition, certain cancer gene therapy strategies such as antiangiogenesis and tumorcidal genes also need timely and high-level expression. A frequently used solution to this shortcoming is the coinfection of wild-type adenovirus that greatly accelerates and enhances AAV vector-mediated transduction both in vitro and in vivo. 2, 3 However, the improved transduction also comes with a price of unacceptable toxicity due to adenovirus infection. Alternatively, chemical and physical treatments of cells and animals demonstrated variable enhancement of AAV transgene expression but accompanied by considerable toxicity. 2, 3, 13, 14 Recent reports showed that AAV vectors of half size of a wild-type genome could package a ds, hairpin-like genome that is self-complementary. 15 Such vectors can circumvent the ss-to dsDNA conversion. However, the vector was inefficient to produce and laborious to purify because it was a by-product of ssAAV vector production. 15, 16 To generate AAV vectors that predominantly package the dsDNA genome, we have mutated one of the AAV inverted terminal repeats (ITRs). This mutation led to nearly exclusive packaging of hairpin-like, dsAAV DNA genomes. Examination of the dsAAV vector in vitro and in vivo and molecular characterization of the vector DNA support the conclusion that dsAAV vectors render superior gene transfer over the conventional ssAAV vectors.
Results

Efficient packaging of dsAAV after mutation of one ITR
A ssAAV DNA genome is flanked by two ITRs of 145 bases (Figure 1a and b) . The 3 0 ITR serves as a replication origin and a packaging signal. 17 AAV replication intermediates include head-to-head and tail-to-tail dimer DNA molecules. The dimers are cleaved by AAV Rep proteins at the junction ITR to yield monomers. Each monomer is then packaged into an AAV particle as ssDNA (Figure 1b, left panel) . However, if one of the ITRs (for example, the left ITR) is deleted of D-sequence (the packaging signal) together with the adjacent terminal resolution site (trs) (Figure 1a and b, right panel), then the dimers fail to be resolved into monomers. Nonetheless, each dimer can still be packaged via the remaining wild-type ITR into AAV particles in the form of a large hairpin DNA, hence a ds genome ( Figure  1b, right panel) .
To generate AAV vectors that predominantly package the ds hairpin-like dimer DNA, we have deleted the Dsequence and the trs of the left ITR on the AAV vector while keeping the right ITR intact (Figure 1a ; see section Materials and methods). Furthermore, the entire AAV vector genome was made smaller than 2.5 kb so that a dimer molecule can be packaged without exceeding the viral packaging limit of 5 kb. Using the enhanced green fluorescent protein (GFP) as the reporter gene, we have produced both ssAAV and dsAAV vectors based on AAV serotype 2 ( Figure 1a ) and obtained very similar titers as determined by DNA dot blot method (data not shown), indicating that the deletion of D-sequence on one ITR did not affect the efficiency of viral replication and packaging. The dsAAV particles were readily purified by a single-step heparin affinity column chromatography without the need for the tedious density-gradient ultracentrifugation. 18 By contrast, the centrifugation step was a requirement for the purification of the early version dsAAV, because it was a minor product among the ssAAV monomers. 15, 16 By deleting the D-sequence and the trs on the left ITR, we have prevented the monomer formation and made the head-to-head dimers as the predominant product. Analysis of the purified vector DNA by neutral agarose gel electrophoresis confirmed that the dsAAV DNA was a ds hairpin of 2.2 kilo-base pair, while the conventional ssAAV DNA migrated faster in the gel as a ss molecule of 4.5 kilonucleotides (kilo-nt) next to the 2 kb dsDNA marker (Figure 1c , left). As expected, the dsAAV hairpin in the alkaline agarose gel was denatured into a 4.4 kilo-nt linear ssDNA, and migrated faster than the 4.5 kilo-nt conventional ssAAV DNA (Figure 1c, right) . No detectable linear ss monomers of 2.2 kilo-nt were present in the alkaline gel, indicating that the dsAAV particles predominantly packaged the dimer hairpin DNA.
Dramatic improvement of transduction by dsAAV vector in vitro
To examine if the dsAAV vectors can transduce more effectively than the ssAAV vectors in vitro, we have compared these vectors in more than 20 cell lines of human, monkey and rodent origins. In the commonly used 293, HeLa and COS-7, the dsAAV-CMV-GFP vector yielded 10-20% green fluorescent cells 1 day after infection at a dose of 500 v.g. (viral genome)/cell without the coinfection of adenovirus. The control ssAAV-CMV-GFP vector yielded less than 1% green fluorescent cells under the same condition. On day 3 after infection, the dsAAV turned 80-100% of the cells green with intense fluorescence, while the ssAAV had approximately 10% of the cells green with dim fluorescence (data not shown). Because the above cell lines are highly permissive for ssAAV vectors, we further examined a number of cell lines that have been shown as very difficult to be transduced by ssAAV, for example, the B16 melanoma, 3LL Lewis lung carcinoma and NIH3T3 fibroblast. 19, 20 Our results showed that the dsAAV could effectively transduce the above cells and yield overwhelmingly more green cells than the ssAAV did (Figure 2a ). Furthermore, a dsAAV vector carrying the gene of a secretable protein (angiostatin) also showed much faster transduction than the ssAAV counterpart (Figure 2b) . In all the cell lines tested thus far, we have consistently observed superior transduction by dsAAV over ssAAV.
Accelerated and long-term transduction by dsAAV vector in vivo
It has been well documented that the ssAAV vectors can efficiently transduce muscle tissues but at a slow pace. We therefore compared the time course and efficiency of dsAAV versus ssAAV in mouse leg tibialis anterior (TA) muscle by intramuscular injection of 1 Â 10 11 v.g. of either the ds or the ss GFP reporter vectors. Our results showed For the analysis on neutral agarose gel (0.8%), the viral DNA dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) was boiled for 5 min and quickly chilled on ice before loading. The standard DNA marker (M) was loaded without boiling and therefore still in the ds form. Note that the dsAAV DNA hairpin quickly snapped back into the 2.2 kb dsDNA, while the ssAAV DNA (4.5 kilonucleotides) remained in ss form and migrated aberrantly next to the 2 kb dsDNA marker. For the analysis on alkaline denaturing agarose gel (0.8%), the viral DNA or the DNA marker (M) was dissolved in 100 mM NaOH, 1 mM EDTA for denaturation. Note that the dsAAV DNA was denatured into a 4.4 kilo-nt ssDNA while the ssAAV DNA remained as a 4.5 kilo-nt ssDNA. Both DNAs migrated with expected molecular weight next to the denatured DNA marker (M). , panels H and I). The GFP expression after dsAAV treatment was so intense that the muscle turned green and could be observed without the need of a microscope (Figure 3a , panels E and J). Throughout the entire 6-month time course, the dsAAV gene expression was at a minimum of 15 times stronger than that of the ssAAV. (The photographic exposure time of ssAAV-treated muscles in Figure 3a was 15 times as long as the dsAAV-treated muscles. However, the dsAAV-treated muscles still showed stronger fluorescence than the ssAAV-treated ones.) We next compared the time course and efficiency of dsAAV-versus ssAAV-mediated transgene expression in the liver. It has been reported that ssAAV transduction is slow and restricted to a small fraction (o10%) of the hepatocytes even with high vector doses. 4, 21 We administered dsAAV or ssAAV GFP vectors intravenously at a dose of 2 Â 10 11 v.g. per mouse. By 3 days after vector injection, dsAAV-treated liver showed 2-5% of the hepatocytes expressing GFP. The GFP-positive hepatocytes increased to more than 10% in the liver by 1 week and to more than 50% by 2 weeks (Figure 3b , panels A-C). Up to 90% of the hepatocytes became GFP positive and roughly one-third of those cells had very intense GFP expression by 2 months (Figure 3b , panel D) after dsAAV vector injection and maintained the high levels to the end of the 6 months duration of the experiment (panel E). In contrast, the ssAAV-treated liver had no detectable GFP expression until 2 weeks after vector injection (Figure 3b , panels F-H). The GFP expression increased slightly by 2 months and continued to increase up to 6 months; nevertheless, no more than 2% of the total hepatocytes became transduced. In comparison, the livers treated with dsAAV displayed more green hepatocytes in 3 days than the livers treated with ssAAV in 2 weeks (Figure 3b, panel A versus H) , and displayed similar numbers of green cells as the livers treated with ssAAV for 2 months (Figure 3b, panel A versus I) . These results strongly demonstrate that dsAAV can achieve 
Molecular analysis of AAV genomes in liver
To investigate if the ds-and ssAAV genomes had different molecular fate in vivo, especially in the liver, we performed Southern analysis of the liver DNA isolated at various time points after vector injection, from 3 days, 2 weeks, 2 months to 6 months. A fragment of GFP gene, common for both ds-and ssAAV vectors, was used as the probe. At 3 days after injection, the dsAAV vector was primarily in the form of linear dsDNA of 2.1 kb (Figure 4a , lane 2, also see Figure 1b and c for diagrams), which was confirmed by BamHI digestion that cut once in the genome (lane 7, and diagram below). By 2 weeks, approximately half of the input linear dsDNA was converted to the supercoiled (sc) circular monomer DNA that migrated faster in the agarose gel than the linear DNA (Figure 4a, lane 3) . The sc circular DNA could be linearized by BamHI digestion into a 2.1 kb unit-length dsAAV genome (lane 8, upper band), whereas the remaining input linear viral genome was digested into two fragments of 0.83 and 1.27 kb (lane 8, lower band). By 2 months and up to 6 months, the linear input dsAAV genomes were no longer detectable. They were converted primarily to the sc circular monomer DNA (Figure 4a , lanes 4 and 5, and 9 and 10). Interestingly, the rapid and efficient conversion of the linear dsDNA to the sc circular DNA appeared to corroborate the rapid and efficient transgene expression of dsAAV in the liver (Figure 3b , panels A-E).
Another important observation was the much higher in vivo vector DNA stability of dsAAV than the ssAAV (comparing Figure 4a and b) . The input dsAAV vector DNA did not decline significantly from 3 days to 6 months ( Figure 4a, lanes 12-15) , maintaining an average of 4-5 copies per cell. In contrast, the input ssAAV vector DNA declined rapidly from 3 days to 2 weeks, and further declined until 2 months post-vector injection (Figure 4b) , maintaining an average of 0.2 copies per cell. Furthermore, the majority of the ssAAV DNA remained in the ss form in the first 2 weeks (Figure 4a , lanes 4 and 5, and 9 and 10), and was slowly converted to sc circular dsDNA and high-molecular-weight DNA by 2-6 months (Figure 4b, lanes 11 and 12) . The sc circular dsDNA was confirmed by SacI digestion into a linearized unit-length dsDNA (Figure 4b , lanes 6 and 7; note the disappearance of the sc DNA as seen in lanes 11 and 12) . The rapid decline of input vector, the slow and inefficient conversion of ssDNA to sc circular dsDNA also corroborates the delayed and weaker transgene expression of ssAAV vectors in the liver (Figure 3b , panels F-J).
Discussion
Here we have presented a new strategy for efficient production of dsAAV vectors and demonstrated the usefulness of these vectors both in vitro and in vivo for accelerated and robust transgene expression. The dsAAV not only rendered much improved transduction in cells that are highly permissive for ssAAV, but also overcame barriers in the poorly permissive cells. For example, the melanoma B16F10 cell is a very difficult cell line for ssAAV to transduce. This limited transduction has been attributed to the low abundance of the AAV2 cell surface receptor. 19 However, the dsAAV was able to transduce efficiently the B16F10 cells (Figure 2a) . Since both the ss-and dsAAV vectors used identical viral capsids, the profound difference in transduction efficiencies could not be accounted for by the lack of cell surface receptors. In addition, another cell line NIH3T3 fibroblast was readily transduced by the dsAAV but only slightly transduced by the ssAAV (Figure 2a) , although both NIH3T3 and the permissive 293 cells had similar binding capacity to AAV2, 22 again suggesting that factors other than the receptor play an important role. The dsAAV also showed superior transduction in primary islet and neural stem cell cultures (data not shown). Our in vitro results demonstrated that the dsAAV vector genome could effectively circumvent the key rate-limiting step of ssDNA to dsDNA conversion. These findings should facilitate new applications of dsAAV in gene therapy for cancer, diabetes and neural degenerative diseases.
The in vivo results also support the conclusion that the effectiveness of dsAAV transduction is achieved at the post-cell-entry levels, because the parallel studies using ds-and ssAAV vectors were performed on the same tissues but revealed profound differences. Of particular interest is the transduction in the liver. The mediocre efficiency in our studies using the ssAAV vector was consistent with the results by others. 9, 21 Song et al 9 reported that after administration of 3 Â 10 10 infectious 3-7) . The ss vector DNA (SS) is indicated by a gray arrowhead. The plasmid DNA was used as a copy number control ranging from two copies (lane 2) to 10 copies (lane 1) per cell. The autoradiograph was obtained after exposure against the X-ray film for 2 weeks.
Double-stranded AAV vector transduction Z Wang et al units of ssAAV-GFP vector into the liver, only a small portion of hepatocytes (about 5%) expressed the transgene. Kay and co-workers showed similar results (o10% transduction) with ssAAV vector containing the clotting factor IX gene or beta-galactosidase gene in the liver at doses up to 3.9 Â 10 12 genomes/animal. 8, 21 They concluded that only a small fraction of the hepatocytes was permissive for ssAAV transduction despite the fact that most of the hepatocytes had taken up the viral DNA, as being demonstrated by in situ hybridization 8 and by adenovirus infection. 3 Adenovirus effectively converted the transcriptionally inactive ssAAV vector DNA into functional templates in the majority of the hepatocytes. 3 The capability of dsAAV to render high-level transgene expression in the majority of the hepatocytes substantiates the notion that ss-to dsDNA conversion is a major barrier for ssAAV transduction in vivo, particularly in the liver, irrespective of how the ssDNA was converted to dsDNA, either by second-strand DNA synthesis 2, 3 or by annealing of the plus and minus strands of two ss vector genomes. 4 The double-strandedness of the AAV genome appears not to be the sole factor that contributes to the high efficiency of dsAAV. Unlike other dsDNA vectors such as adenovirus and plasmid DNA, dsAAV-mediated transduction does not rapidly decline with time. Its transgene expression increases with time, especially in vivo, suggesting continuous recruitment and conversion of the dsAAV genomes into transcriptionally active templates. Southern blot analyses of the ds-and ssAAV vector DNA isolated from the livers at different intervals ( Figure 4 ) not only revealed higher in vivo DNA stability of the dsAAV, but also showed more efficient conversion into sc circular DNA (comparing Figure 4a and b) . When identical doses of viral genome particles (each dsAAV is considered as two ssAAV) were administered, the dsAAV DNA persisted more effectively than the ssAAV DNA throughout the time course in the liver. The copy numbers of dsAAV were more than 10 times higher than the ssAAV 2 months after vector administration. It is plausible to believe that the higher vector genome stability also contributed to the higher in vivo transduction efficiency. Another interesting phenomenon is the more effective conversion of linear vector DNA to the circular sc form. 23 A high proportion of the dsAAV in the liver persisted as the sc monomer (Figure 4a ). Since the sc DNA is transcriptionally more active than the linear DNA, 24 it is reasonable to speculate that the gradual increase of sc dsDNA may be responsible, in a major part, for the gradual increase of gene expression in vivo. A recent study of ssAAV dose escalation in liver indicated that the gene expression levels correlated more closely with the formation of sc vector DNA than with the high-molecular-weight concatemers. 21 Long-term persistence of the sc vector DNA in vivo has been reported in numerous cases including in tissues such as the lung, 14, 25 muscle 23, 26 and liver. 9, 27 Whether the sc vector DNA is the primary contributor to the transgene expression in vivo remains to be seen. Interestingly, in dsAAV-transduced livers, the vector DNA primarily remained as the circular low-molecular-weight episomal DNA, whereas the ssAAV vector transduced livers had much more high-molecular-weight DNA, which could be either multimers of vector DNA and/ or integrated forms, suggesting that rapid conversion of dsAAV into circular monomers does not favor the formation of high-molecular-weight DNA.
A major drawback of the dsAAV is its decrease in the size of foreign genes that can be packaged. An AAV viral particle can usually package approximately 5000 nucleotides of ssDNA. The dsAAV vectors in effect contain two copies of the ssAAV cassette in a head-to-head hairpin form ( Figure 1) . As a result, each vector cassette including the ITRs could not exceed 2.5 kb in size for efficient packaging. When common promoters such as the CMV, CB and MCK are used, a cDNA of about 1.2 kb can be packaged into the dsAAV. While such packaging size excludes many candidate genes, it is still useful for a large number of genes that encode for cytokines, growth factors, other secretable proteins (eg, endostatin and angiostatin), muscle proteins (eg, sarcoglycans) and small RNA genes (ribozymes, 5 antisense 28 and small interference RNA 29 ) for the purposes of prompt, robust and prolonged transgene expression.
Materials and methods
Cell lines
Human cell lines including 293, cervical cancer HeLa, prostate cancer PC3, DU145, TSU and LNCaP, colon cancer HCT116, follicular thyroid carcinoma FTC133, head and neck cancer 1483, osteosarcoma cell SaOS2, glioma U87, breast cancer MCF7 and BT549, hepatocarcinoma HepG2 and monkey kidney cell COS-7 and murine cell lines melanoma B16 and liver cancer Hepa1-6 and Lewis lung carcinoma 3LL and NIH3T3 fibroblast, and Chinese hamster ovary (CHO) cell were obtained from American Type Culture Collection (Rockville, MD, USA) or from various laboratories.
AAV vector construction and production
The conventional AAV-CMV-GFP vector plasmid ( Figure  1a ) was published earlier. 30 The AAV vector plasmid dsAAV-CMV-GFP (Figure 1a ) that generates ds viral DNA was constructed by deleting the D-sequence of the 5 0 ITR with MscI digestion. MscI removed the D-sequence and the terminal resolution site (trs) (nucleotides 122-144 of AAV2 genome, GenBank #NC_001401). The ITR on the 3 0 terminus of the vector remained intact (wild type). To make the vector smaller than 2.5 kb for dsAAV packaging, the Neo r cassette was also deleted (Figure 1a ). Plasmid dsAAV-CMV-angiostatin was made by replacing the GFP gene and the SV40 polyA site of dsAAV-CMV-GFP with the angiostatin cDNA coupled with a miniature polyA site. For stable liver gene expression, the CMV promoter was replaced by the CB promoter (CMV enhancer/chicken beta-actin promoter), generating plasmids ssAAV-CB-GFP and dsAAV-CB-GFP. The recombinant viral stocks were produced by the adenovirus free, triple-plasmid cotransfection method. 30 The AAV particles were subsequently purified by heparin affinity column chromatography. 18 Titers of viral genome (v.g.) particle number were determined by quantitative DNA dot blot method. 31 Each dsAAV particle was calculated as containing two copies of ss viral genome (versus one copy in each conventional ssAAV particle). All AAV vectors used in this study were from AAV serotype 2. 
In vitro and in vivo infection
For the in vitro assays, 2 Â 10 5 cells were seeded in each well of a six-well plate 1 day before infection. AAV vectors diluted in DMEM medium were added to the cell culture without wild-type adenovirus coinfection. The GFP expression was examined 1 day and 3 days after infection on a Nikon TE-300 inverted fluorescent microscope. The secretion of angiostatin in culture medium was detected by immunoprecipitation (IP) Western blot as described previously. 6 For in vivo assays in the muscle and liver, female C57/B10 mice (8-10 weeks of age) were used (Jackson Laboratory, Bar Harbor, ME, USA). Tibialis anterior muscles were injected with 50 ml (1.0 Â 10 11 total viral genome particles) of either the ss (ssAAV-CMV-GFP) or the ds (dsAAV-CMV-GFP) AAV vectors. For liver gene transfer, 200 ml (total 2 Â 10 11 viral particles per mouse) of either ssAAV-CB-GFP or dsAAV-CB-GFP was injected intravenously. Muscle and liver samples were collected at various time points for analysis. For the detection of GFP expression in the muscle and liver, cryo thin sections (8 mm) were directly mounted with Gel/ Mount (Biomeda, Foster City, CA, USA) and observed under Nikon TE-300 inverted fluorescent microscope.
Southern analysis of liver tissue DNA
Liver tissues were harvested, minced and suspended in lysis buffer (10 mM Tris-HCl, 100 mM EDTA, 0.5% SDS and 100 mg/ml proteinase K, pH 8.0). The samples were digested at 371C overnight and incubated for additional 2 h after adding 20 mg/ml RNase A. After phenol, phenol-chloroform and chloroform extraction, the total DNA (both low-and highmolecular-weight DNA) was precipitated with 0.3 M sodium acetate and 2.5 volumes of ethanol and by centrifugation, washed twice with 70% ethanol and redissolved in TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). Restriction enzyme digestions (New England BioLabs) were carried out overnight. DNA samples were ethanol-precipitated after digestion to remove extra salt before they were separated on a 0.8% agarose gel. Southern hybridization was performed with GeneScreen Plus membrane according to the manufacturer's standard protocol (NEN-DuPont). The EGFP DNA probe was a 0.7 kb BamHI and NotI fragment labeled with alpha-32 P dATP and Random Primer Kit (Boehringer Mannheim).
